Iridex ophthalmic laser system for glaucoma treatment receives CE Mark approval
Ophthalmology laser systems, delivery devices, and consumables maker Iridex (Mountain View, CA) has received its CE Mark to commercialize across Europe its Cyclo G6 laser system for use in treating glaucoma and its symptoms. The system is dedicated specifically to treating patients diagnosed with a range of glaucoma disease states, and features the company’s proprietary MicroPulse tissue-sparing technology and a family of single-use probes that connect to a laser console.
Dr. Keith Barton, Consultant Ophthalmologist, Glaucoma Service at Moorfields Eye Hospital (London, England) says that some studies that have used the Cyclo G6 system have shown a 30-40% reduction in intraocular pressure (IOP) without incisions or using implants.
The system will be sold with two disposable probes, the MicroPulse P3 probe for use with a broad range of glaucoma patients, and the G-Probe for later stage patients. The company plans to introduce a series of additional new probes in 2016 that allow for additional applications in glaucoma treatment.
For more information, please visit www.iridex.com.
BioOptics World Editors
We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)